Nachrichten

Once dismissed as an outdated remedy, leech therapy—known in medical terms as hirudotherapy—has firmly re‑entered the spotlight of 21st‑century medicine. Over the past two decades, regulatory agencies including the U.S. Food and Drug Administration (FDA) have formally approved medicinal leeches for specific clinical uses, while an expanding body of clinical research is validating their effectiveness in treating thrombotic disorders, chronic venous insufficiency, post‑surgical venous congestion, and various inflammatory conditions.

In this article, we examine how leech therapy works, review the scientific evidence supporting its modern applications, and present real‑world case studies illustrating its clinical benefits.

The therapeutic use of leeches dates back thousands of years, but their transition into evidence‑based medicine is a relatively recent phenomenon. In 2004, the FDA approved medicinal leeches (Hirudo medicinalis) as medical devices, specifically designating them as “an adjunct to graft tissue healing when problems of venous congestion may delay healing". In 2024–2026, oversight was formally transferred to the FDA’s Center for Biologics Evaluation and Research (CBER), placing medicinal leeches under the “Blood & Blood Products" classification—a regulatory classification unique to a living organism.

Today, major hospitals maintain tanks of medicinal leeches for specific surgical procedures, particularly in plastic and reconstructive surgery, microsurgery, and digit replantation.

The therapeutic power of medicinal leeches lies in their saliva, which contains a sophisticated cocktail of pharmacologically active substances. The most renowned of these is hirudin, a 65–66 amino acid peptide that is among the most potent natural thrombin inhibitors known. Hirudin works by binding directly and irreversibly to thrombin—the central enzyme in the coagulation cascade—thereby preventing the conversion of fibrinogen into fibrin and inhibiting thrombin‑induced platelet aggregation.

Unlike heparin, which requires antithrombin III as a cofactor, hirudin acts directly on thrombin and remains effective even against clot‑bound thrombin, offering a significant advantage in preventing re‑thrombosis. Research has shown that recombinant hirudin is particularly effective against venous‑type thrombi and demonstrates greater anti‑thrombotic effects on platelet‑rich arterial thrombi compared to conventional heparins.

Beyond hirudin, leech saliva contains over 100 biologically active enzymes and compounds, including:

• Hyaluronidase: Enhances tissue permeability, facilitating the diffusion of other active substances

• Calin and apyrase: Inhibit platelet adhesion and aggregation

• Antimicrobial peptides: Reduce local infection risk

• Various anti‑inflammatory and analgesic substances

Scientific studies have confirmed that leech saliva possesses anti‑inflammatory, anticoagulant, analgesic, antibacterial, vasodilator, and anesthetic activities, making it a uniquely versatile therapeutic agent.

Perhaps the most widely documented modern application of leech therapy is in the management of venous congestion following reconstructive microsurgery.

In a recent study published in Revista Medico‑Chirurgicală (2025), researchers evaluated medicinal leech therapy in 35 patients who developed venous congestion after digital replantation (re‑attachment of severed fingers). In such procedures, achieving adequate venous outflow can be technically challenging or even impossible, placing the re‑attached tissue at risk of necrosis.

The results were compelling:

• The overall tissue salvage rate was 88.6% (31 of 35 cases)

• Reported salvage rates in the literature range from 66% to 85%

• Treatment typically started within 24–48 hours of congestion onset

• Therapy lasted 4–7 days, with 2–5 leeches applied daily at 2–4‑hour intervals

The study concluded that “MLT remains an effective, evidence‑supported adjunct for venous congestion management after digital replantation, particularly when venous anastomoses are not feasible". This underscores the irreplaceable role of living leeches in situations where no synthetic alternative currently exists.

Chronic venous insufficiency and varicose veins affect hundreds of millions worldwide, often leading to painful, non‑healing ulcers that dramatically reduce quality of life.

A 2025 case report in the Journal of Ayurveda and Integrated Medical Sciences documented the successful treatment of a 48‑year‑old male patient with a chronic, non‑healing ulcer on the right lower leg associated with varicose veins. The patient underwent weekly leech therapy (Jaloukavacharana) for 11 weeks, combined with topical wound dressing.

Results showed progressive improvement, with complete ulcer healing observed after 11 weeks. The authors noted that “the integrated use of leech therapy […] can be an effective and safe alternative in managing venous leg ulcers," with no adverse effects reported.

Similarly, a 2023 case study described a 47‑year‑old female patient suffering from an intensely painful varicose ulcer on the lower leg for six months. After four sessions of leech therapy, significant improvement was observed in wound healing, pain reduction, and swelling.

A 2022 case series further confirmed that leech therapy “significantly reduce[d] venous engorgement by resolving edema, inflammation, and venous congestion" in patients with lower‑extremity varicose veins.

In an even more striking example, a 2024 case report documented a patient with three non‑healing ulcers on both lower limbs that had persisted for 27 years despite conventional treatments. After a six‑week course of leech therapy (once weekly), two ulcers healed completely, and the third showed substantial partial healing. The researchers concluded that leech therapy “represents a viable, cost‑effective treatment for chronic ulcers and thromboembolic disorders, especially when conventional methods fail".

Beyond anticoagulation and circulatory applications, leech therapy is increasingly recognized for its potent anti‑inflammatory and pain‑relieving properties.

A 2025 case report described a 40‑year‑old female patient who developed severe infusion phlebitis (inflammation of a vein) at an intravenous cannula insertion site post‑surgery. The patient experienced intense pain, swelling, and severely restricted hand movement. After a single application of leech therapy, pain and swelling were significantly relieved, redness decreased, and the patient regained painless hand movement within 24 hours.

In a more controlled setting, a randomized clinical trial investigated a topical gel formulated from medical leech saliva extract in patients with knee osteoarthritis. After one month of daily application, patients’ pain was reduced by approximately 50%, with significant improvements in joint inflammation, stiffness, and overall quality of life (p < 0.001).

A separate randomized controlled trial comparing leech therapy to topical diclofenac for chronic lateral epicondylitis (tennis elbow) found that leech therapy was superior in reducing pain and disability in the short term, with benefits maintained 15 days after treatment completion.

These findings highlight the broad therapeutic potential of leech‑derived bioactive compounds in managing inflammatory conditions across multiple clinical contexts.

The effectiveness of medicinal leech therapy depends critically on the quality, health, and bioactive potency of the leeches themselves. In China, the Japanese medical leech (Hirudo nipponia Whitman) is recognized as a premier source of antithrombin‑active compounds. Research has demonstrated that Hirudo nipponia exhibits potent anti‑thrombin activity and effectively inhibits platelet aggregation, while other leech species show only weak or even contradictory effects.

The Chinese Pharmacopoeia has established specific quality standards, requiring an antithrombin activity of not less than 16.0 units per gram for raw leeches, ensuring that medicinal leeches used in clinical applications meet strict potency criteria.

Professional farming facilities must adhere to standardized production and processing protocols—such as the Chinese technical code T/CACM 1571.13‑2024—which govern site selection, feeding management, disease prevention, harvesting, and processing procedures. These standards ensure:

• Consistent antithrombin activity across production batches

• Freedom from pathogens, contaminants, and microplastics

• Biosecurity and traceability throughout the supply chain

• Humane and sustainable rearing practices

At Jingzhou Minkang Biotechnology Co., Ltd. , we have pioneered the farming and deep processing of Hirudo nipponia in accordance with these rigorous standards. Our integrated operations—from controlled propagation and feeding protocols to advanced processing technologies—ensure that our medicinal leeches and leech‑derived products meet the highest quality benchmarks for both domestic and international markets.

While living leeches remain indispensable in certain surgical contexts (particularly where mechanical alternatives do not yet exist), leech‑inspired biotechnology is advancing rapidly.

Recent developments include:

• Recombinant hirudin produced via genetic engineering in yeast and plant systems, enabling scalable production of this potent anticoagulant

• Hirudin‑based fusion protein prodrugs integrated into microneedle patches for long‑term, self‑administered antithrombotic therapy—a biomimetic approach directly inspired by leech mouthpart anatomy. These patches provide continuous protection for up to one week without increasing bleeding risk

• Topical formulations of leech saliva extract for osteoarthritis and other inflammatory conditions, offering needle‑free, convenient local therapy

• Ongoing research into synthetic aptameric hirudin variants as reversible exosite‑active site (EXACT) inhibitors, promising next‑generation anticoagulants with improved safety profiles

As pharmaceutical scientists continue to draw inspiration from leech biology, the pipeline of leech‑derived and leech‑inspired therapeutics will continue to expand.

Far from being a relic of medical history, leech therapy has earned its place in 21st‑century medicine through rigorous regulatory approval, robust clinical evidence, and continued innovation. From salvaging threatened replanted digits and healing varicose ulcers to relieving inflammatory pain, medicinal leeches—and the bioactive molecules they produce—offer unique therapeutic benefits that synthetic alternatives have yet to fully replicate.

With modern farming standards ensuring consistent quality and potency, and with biotechnology unlocking new applications beyond living therapy, the future of leech‑based medicine is brighter than ever.

At Jingzhou Minkang Biotechnology Co., Ltd. , we are proud to be at the forefront of this remarkable convergence of nature and science—breeding high‑potency Hirudo nipponia and developing value‑added leech products for global healthcare markets.

This article is for informational purposes only and does not constitute medical advice. Leech therapy should only be administered by qualified healthcare professionals in appropriate clinical settings.

About the Author – Jingzhou Minkang Biotechnology Co., Ltd. is a leading producer and deep‑processor of the Japanese medicinal leech (Hirudo nipponia), supplying premium leeches and leech‑derived products to healthcare providers, research institutions, and pharmaceutical partners worldwide.